Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4297-4305

  Domingo, Enric ^a   Church, David N ^a,b   Sieber, Oliver ^d   Ramamoorthy, Rajarajan ^a,c   Yanagisawa, Yoko ^b   Johnstone, Elaine ^b   Davidson, Brian ^c   Kerr, David J ^b   Tomlinson, Ian P M ^a   Midgley, Rachel ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE 3CA; PLACEBO; ROFECOXIB; UNCLASSIFIED DRUG; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIK3CA PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; SULFONE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; COLON RESECTION; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; COLORECTAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LACTONES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892843686     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.0322     Document Type: Article

References (30)

1. Wang D, Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29:781-788, 2010
2. Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994 (Pubitemid 24294584)
3. Kargman SL, O'Neill GP, Vickers PJ, et al: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556- 2559, 1995
4. Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis 30:377-386, 2009
5. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996 (Pubitemid 26404280)
6. Chulada PC, Thompson MB, Mahler JF, et al: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708, 2000
7. Giovannucci E, Rimm EB, Stampfer MJ, et al: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-246, 1994
8. Thun MJ, Namboodiri MM, Heath CW Jr, et al: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991
9. Bardia A, Ebbert JO, Vierkant RA, et al: Association of aspirin and nonaspirin nonsteroidal antiinflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99:881-889, 2007 (Pubitemid 47073510)
10. Chan AT, Giovannucci EL, Meyerhardt JA, et al: Long-term use of aspirin and nonsteroidal antiinflammatory drugs and risk of colorectal cancer. JAMA 294:914-923, 2005 (Pubitemid 41215460)
11. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369:1603-1613, 2007 (Pubitemid 46710123)
12. Dubé C, Rostom A, Lewin G, et al: The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365-375, 2007 (Pubitemid 351650597)
13. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
14. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890, 2003 (Pubitemid 36297996)
15. Cole BF, Logan RF, Halabi S, et al: Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst 101:256-266, 2009
16. Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682, 2006 (Pubitemid 44958508)
17. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003 (Pubitemid 36297997)
18. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379:1591-1601, 2012
19. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658, 2009
20. Chan AT, Tranah GJ, Giovannucci EL, et al: Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 97:457-460, 2005 (Pubitemid 40528609)
21. Liao X, Lochhead P, Nishihara R, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596-1606, 2012
22. Di Popolo A, Memoli A, Apicella A, et al: IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19:5517- 5524, 2000 (Pubitemid 32000919)
23. Midgley RS, McConkey CC, Johnstone EC, et al: Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial. J Clin Oncol 28:4575-4580, 2010
24. Kerr DJ, Dunn JA, Langman MJ, et al: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357: 360-369, 2007 (Pubitemid 47124136)
25. Domingo E, Ramamoorthy R, Oukrif D, et al: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229:441-448, 2013
26. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101: 1446-1452, 2009
27. O'Connell MJ, Campbell ME, Goldberg RM, et al: Survival following recurrence in stage II and III colon cancer: Findings from the ACCENT data set. J Clin Oncol 26:2336-2341, 2008
28. Din FV, Valanciute A, Houde VP, et al: Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142:1504-1515, 2012
29. Dikshit P, Chatterjee M, Goswami A, et al: Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 281:29228- 29235, 2006 (Pubitemid 44507066)
30. Chan AT, Ogino S, Giovannucci EL, et al: Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799- 808, 2011